IDSA: MVA-BN Vaccine Against Mpox Tolerated, Effective for Teens
By Elana Gotkine HealthDay Reporter
THURSDAY, Oct. 17, 2024 -- The Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine, licensed in the United States to prevent smallpox and mpox, is well tolerated and seems effective in adolescents, according to a study presented at the annual meeting of the Infectious Diseases Society of America (IDWeek), held from Oct. 16 to 19 in Los Angeles.
Catherine Mary Healy, M.D., from Baylor College of Medicine in Houston, and colleagues examined the safety and immunogenicity of two doses of MVA-BN vaccine administered subcutaneously 28 days apart in adolescents aged 12 to 17 years compared to adults (aged 18 to 50 years) in a phase 2, open-label, multisite clinical trial. A total of 315 adolescents were compared to 211 adults.
The researchers found that both groups had similar solicited systemic and local events and unsolicited adverse events. Adolescents had dizziness more often (nine events in eight patients versus none in adults), which was similar to rates reported after other adolescent vaccines. MVA-BN was well tolerated overall. The day 43 antibody responses elicited by MVA-BN in adolescents were noninferior to the response in adults (geometric mean titer ratio for adolescents to adults, 1.60).
"These findings mark an important milestone for people living in areas with mpox," Healy said in a statement. "This mpox vaccine is an increasingly important solution to protect vulnerable adolescents and manage current and future outbreaks."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted October 2024
Read this next
Worse Outcomes Seen for Unvaccinated Patients Hospitalized With COVID-19, AKI
WEDNESDAY, June 18, 2025 -- For patients hospitalized with COVID-19 infection and acute kidney injury (AKI), those who are unvaccinated have worse outcomes in terms of kidney...
Virtual Reality Training Module May Aid Infection Control Efforts
TUESDAY, June 17, 2025 -- Users report positive experiences and engagement with a virtual reality tool that trains clinicians on core concepts in infection control, including...
2,770 Cases of Arboviral Disease Reported in 48 States and D.C. in 2023
TUESDAY, June 17, 2025 -- In 2023, 48 states and the District of Columbia reported 2,770 human arboviral disease cases, with West Nile Virus (WNV) being the most common, according...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.